Form 4 Filing for Celldex Therapeutics, Inc. - Officer Stock Option Grant

This filing details a Form 4 submission for Celldex Therapeutics, Inc. concerning a stock option grant to Margo Heath-Chiozzi, SVP of Regulatory Affairs. On June 25, 2026, Ms. Heath-Chiozzi was granted 95,000 Incentive Stock Options under the company's 2021 Omnibus Equity Incentive Plan. The options have an exercise price of $34.09 and are exercisable starting June 25, 2027. The vesting schedule indicates that 25% will vest on June 25, 2027, with the remainder vesting quarterly over the subsequent 12 months. The transaction is reported as direct ownership, with the post-transaction shares owned at 95,000.